Crohn’s Disease Therapeutics Market

Crohn’s Disease Therapeutics Market by Therapy Type (Non-Surgical [Anti-Inflammatory, Immune system suppressors, Antibiotics, and Others], and Surgical), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1197
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 135
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global Crohn’s disease therapeutics market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing disease prevalence, along with a growth in the number of pipeline drugs.

Crohn's disease is an inflammatory bowel illness that affects the intestines (IBD). It causes digestive system inflammation, which can result in stomach discomfort, severe diarrhea, tiredness, weight loss, and malnutrition. Crohn's disease causes inflammation in different parts of the digestive system in different persons. This inflammation frequently extends into the bowel's deeper layers. Crohn's disease is a painful and debilitating condition that can occasionally result in life-threatening complications. While there is no known cure for Crohn's disease, treatments can significantly reduce symptoms and potentially lead to long-term remission and inflammatory healing.

Global Crohn’s Disease Therapeutics Market Summary

Many patients with Crohn's disease can operate normally after receiving therapy. Any region of your small or large intestine can be affected by Crohn's disease, and it can be continuous or encompass numerous segments. The illness is limited to the colon, which is a portion of the large intestine, in some patients. Crohn's disease signs and symptoms can range from minor to severe. They generally appear gradually, although they can sometimes appear suddenly and without notice. There may also be times when you have no indications or symptoms (remission). Diarrhea, fever, fatigue, abdominal discomfort and cramps, blood in your stool, mouth sores, reduced appetite and weight loss, and pain or drainage at or around the anus owing to inflammation from a tunnel into the skin are all signs and symptoms of the illness while it is active (fistula). Inflammation of the skin, eyes, and joints, inflammation of the liver or bile ducts, kidney stones, iron shortage (anemia), and delayed growth or sexual development in children are all symptoms of severe Crohn's disease. Doctor will not be able to identify Crohn's disease just on a single test result. They will start by ruling out any other potential reasons of your symptoms.

To make a diagnosis, your doctor may perform a variety of tests, including Blood tests can assist your doctor in looking for signs of potential issues such as anemia and inflammation. A stool test can assist your doctor in detecting blood in your gastrointestinal system. To acquire a better view of the inside of your upper gastrointestinal system your doctor may recommend an endoscope, a colonoscopy may be ordered by your doctor to check the big intestine, CT scans and MRI scans provide more information to your doctor than a standard X-ray, doctor can view particular regions of your tissues and organs with both tests, during an endoscopy or colonoscopy, your doctor will most likely take a tissue sample, or biopsy, to examine your digestive tract tissue more closely. Although there is no cure for Crohn's disease, the condition can be controlled. There are a number of therapy options available to help you manage the severity and frequency of your symptoms. The treatment options include medications, surgery, and diet. Crohn's disease research is still underway in the terms of achieving more effective therapies and, ultimately, a cure. However, symptoms can be well controlled, and remission is possible.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing prevalence of Crohn’s disease in developing countries as a result of industrialization, environmental variables such as changes in sunlight exposure, dietary changes, smoking, and hereditary characteristics are projected to drive the market growth.
  • Growing efforts on development of biosimilars is anticipated to propel the market growth during the forecast period.
  • Low cost of biosimilars and increased access to biologic therapies are major factors fueling the market growth in the coming years.
  • Increase in the number of pipeline drugs is anticipated to drive the market growth during the forecast period.
  • High costs of deploying essential equipment to treat Crohn's disease is anticipated to impede the market growth during the forecast period.
  • Lack of expertise in providing therapy in rural and underdeveloped areas presents as key challenge that can hamper the market growth during the forecast period.
  • Increased focus on R&D for development of innovative biological agents and anti-cytokine agents with diverse mechanisms of action, as well as the use of stem cells in disease treatment is projected to create lucrative opportunities for the market players.

Scope of the Report

The report on the global Crohn’s disease therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Crohn’s Disease Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapy Type (Non-Surgical [Anti-Inflammatory, Immune system suppressors, Antibiotics, and Others], and Surgical)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited

 

Market Segment Insights

Non-surgical segment is expected to account for a key share
Based on therapy type, the Crohn’s disease therapeutics market is bifurcated into non-surgical and surgical. The non-surgical segment is further sub segmented into anti-inflammatory, immune system suppressors, antibiotics, and others. The non-surgical segment is expected to account for a key share of the market during the forecast period owing to growing adoption of anti-inflammatory drugs. Anti-inflammatories are drugs that are used as first-line treatment as they are more targeted and effective.

On the other hand, the immune system suppressors segment is anticipated to expand at a rapid pace during the forecast period owing to its safety and efficacy. The segment is projected to be driven by lower rates of mortality, hospitalization, and surgery, as well as better patient quality of life. Immune system suppressors are presently being developed by companies like Genentech Inc. and Celgene Corporation to address this disease. For example, Genentech Inc.'s etrolizumab, an immune system suppressor, is now being studied in clinical trials. In phase II clinical trials, this medication showed promise in terms of safety and effectiveness. The approval of these goods might help this market develop in the future.

Global Crohn’s Disease Therapeutics Market By Therapy

North America is anticipated to dominate
On the basis of regions, the Crohn’s disease therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to established R&D infrastructure, the discovery of innovative treatments, and the growing prevalence of the condition. Due to the increasing disease's incidence and well-developed healthcare infrastructure, new treatment approaches are being developed and made available to sufferers.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to change in dietary habits. Japan and China are regarded to be the region's most potential markets.

Europe is expected to exhibit a rapid growth rate in the coming years owing to well-established healthcare infrastructure, as well as an increase in illness prevalence and R&D activities.

Global Crohn’s Disease Therapeutics Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Crohn’s Disease Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Crohn’s Disease Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Crohn’s Disease Therapeutics Market - Supply Chain
  4.5. Global Crohn’s Disease Therapeutics Market Forecast
     4.5.1. Crohn’s Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Crohn’s Disease Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Crohn’s Disease Therapeutics Market Absolute $ Opportunity
5. Global Crohn’s Disease Therapeutics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     5.3.1. Non-Surgical
     5.3.2. Surgical
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Crohn’s Disease Therapeutics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Crohn’s Disease Therapeutics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
7. North America Crohn’s Disease Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Crohn’s Disease Therapeutics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     7.4.1. Non-Surgical
     7.4.2. Surgical
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
8. Latin America Crohn’s Disease Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Crohn’s Disease Therapeutics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     8.4.1. Non-Surgical
     8.4.2. Surgical
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
9. Europe Crohn’s Disease Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Crohn’s Disease Therapeutics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     9.4.1. Non-Surgical
     9.4.2. Surgical
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
10. Asia Pacific Crohn’s Disease Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Crohn’s Disease Therapeutics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     10.4.1. Non-Surgical
     10.4.2. Surgical
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
11. Middle East & Africa Crohn’s Disease Therapeutics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Crohn’s Disease Therapeutics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Crohn’s Disease Therapeutics Market Size and Volume Forecast by Types
     11.4.1. Non-Surgical
     11.4.2. Surgical
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Crohn’s Disease Therapeutics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Crohn’s Disease Therapeutics Market: Market Share Analysis
  12.2. Crohn’s Disease Therapeutics Distributors and Customers
  12.3. Crohn’s Disease Therapeutics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Johnson & Johnson Services Inc.
     12.4.2. Pfizer Inc.
     12.4.3. Allergan
     12.4.4. AbbVie Inc.
     12.4.5. Takeda Pharmaceutical Company Limited
     12.4.6. Celgene Corporation
     12.4.7. Perrigo Company PLC
     12.4.8. Ferring B.V.
Segments Covered in the Report
The global Crohn’s disease therapeutics market has been segmented on the basis of

Therapy Type
  • Non-Surgical
    • Anti-Inflammatory
    • Immune system suppressors
    • Antibiotics
    • Others
  • Surgical
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Allergan
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Celgene Corporation
  • Perrigo Company PLC
  • Ferring B.V.
  • Salix Pharmaceuticals
  • Gilead Sciences Inc.
  • Genentech Inc.
  • UCB India Private Limited

Key players competing in the Crohn’s disease therapeutics market includes Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

Global Crohn’s Disease Therapeutics Market By Key Players

Buy Report